Business
Highly Anticipated Omnipod® 5 Real-World Evidence to be Presented at the 16th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD)
ACTON, Mass.--(BUSINESS WIRE)-- Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its
About this update from Insulet Corporation
[{"type":"text","content":" ACTON, Mass.--(BUSINESS WIRE)--\nInsulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced the presentation of new real-world evidence related to the Omnipod® 5 Automated Insulin Delivery System at the 16th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) taking place February 22 – 25, 2023 in Berlin, Germany, and online.\n\nThe first release of Omnipod 5 real-world data will be presented at Insulet’s symposium1, “Innovating Today for a Better Tomorrow: How Omnipod 5 Automated Insulin Delivery System is Changing Diabetes Care.” The Insulet-sponsored symposium will take place on Wednesday, February 22, from 4:15 to 5:45 p.m. CET.\n\n“This dataset is the first preview of how Omnipod 5 is being used across a variety of age groups and other demographics throughout our customer base, which is incredibly exciting,” said Dr. Trang Ly MBBS, FRACP, PhD, Insulet Senior Vice President and Medical Director. “It tells the story of how this system is impacting our users’ daily management of type 1 diabetes, and we can’t wait to share our insights at ATTD.”\n\n“This Omnipod 5 real-world dataset is striking in that it includes all users, since everyone is connected to the cloud-based system,” said Cari Berget MPH, RN, CDCES, Instructor, University of Colorado School of Medicine, who will discuss the data as part of her symposium presentation. “With this large sample and limited selection bias, we see strong time in target range and minimal time below range, exceeding glycemic targets on average. This is extremely promising for long-term benefit in the real world with this device.”\n\nThe symposium, chaired by Dr. Emma Wilmot MB ChB, PhD, Associate Professor, University of Nottingham, will explore the role of the healthcare provider in removing barriers to pump adoption and will provide best practices for optimizing care with Omnipod 5. Dr. Ly will also present plans for future clinical trials and innovations at Insulet.\n\nOmnipod 5 received CE Mark under the Medical Device Regulation (MDR) in September 2022 and has been fully available in the United States since August 2022. The Company plans to launch Omnipod 5 to customers in the United Kingdom mid-year and Germany toward the end of this year.\n\nCl...